Quick Answer
ANAVEX LIFE SCIENCES CORP. reported Net Income of -$46.38 million for fiscal year 2025.
ANAVEX LIFE SCIENCES CORP. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$46.38M -7.8% |
-$43.00M +9.5% |
-$47.51M +1.0% |
-$47.98M -26.6% |
-$37.91M -44.2% |
-$26.28M +0.1% |
| Diluted EPS | -$0.54 -3.8% |
-$0.52 +13.3% |
-$0.60 +3.2% |
-$0.62 -14.8% |
-$0.54 | — |
| Total Assets | $103.81M -23.4% |
$135.57M -12.2% |
$154.39M +1.1% |
$152.71M -5.5% |
$161.62M +367.9% |
$34.54M +36.4% |
| Cash and Equivalents | $102.58M -22.4% |
$132.19M -12.5% |
$151.02M +1.3% |
$149.16M -1.9% |
$152.11M +420.0% |
$29.25M +31.8% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $94.87M -21.1% |
$120.26M -15.2% |
$141.85M -0.4% |
$142.49M -5.5% |
$150.82M +453.7% |
$27.24M +34.2% |
| R&D Expense | $37.59M -10.1% |
$41.84M -4.3% |
$43.72M +15.3% |
$37.92M +15.0% |
$32.98M +30.7% |
$25.23M +13.3% |
| Operating Income | -$51.41M +2.8% |
-$52.88M +5.2% |
-$55.76M -9.4% |
-$50.99M -21.4% |
-$42.00M -35.1% |
-$31.09M |
| Shares Outstanding | 86.67M +2.2% |
84.80M +3.3% |
82.07M +5.3% |
77.94M +2.7% |
75.92M +22.4% |
62.05M +17.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | December 31, 2025 | -$5.68M | +53.1% | +57.1% |
| Diluted EPS | December 31, 2025 | -$0.06 | +57.1% | +62.5% |
| Total Assets | December 31, 2025 | $132.99M | +7.2% | +28.1% |
| Cash and Equivalents | December 31, 2025 | $131.75M | +9.1% | +28.4% |
| Long-Term Debt | June 30, 2016 | $345.00 | — | +2.4% |
| Stockholders Equity | December 31, 2025 | $126.62M | +14.2% | +33.5% |
| R&D Expense | December 31, 2025 | $4.66M | -55.4% | -53.2% |
| Operating Income | December 31, 2025 | -$6.78M | +50.1% | +53.1% |
| Shares Outstanding | December 31, 2025 | 92.67M | +9.0% | +6.9% |
- ANAVEX LIFE SCIENCES CORP. reported Net Income of -$46.38 million for fiscal year 2025.
- ANAVEX LIFE SCIENCES CORP. showed a decrease of -7.8% in Net Income compared to the prior fiscal year.
- ANAVEX LIFE SCIENCES CORP. reported Diluted EPS of $0.54 per share (loss) for fiscal year 2025.
- ANAVEX LIFE SCIENCES CORP. showed a decrease of -3.8% in Diluted EPS compared to the prior fiscal year.
- ANAVEX LIFE SCIENCES CORP. reported Total Assets of $103.81 million for fiscal year 2025.
- ANAVEX LIFE SCIENCES CORP. showed a decrease of -23.4% in Total Assets compared to the prior fiscal year.
- ANAVEX LIFE SCIENCES CORP. reported Cash and Equivalents of $102.58 million for fiscal year 2025.
- ANAVEX LIFE SCIENCES CORP. showed a decrease of -22.4% in Cash and Equivalents compared to the prior fiscal year.
- ANAVEX LIFE SCIENCES CORP. reported Long-Term Debt of $332.00 for fiscal year 2015.
- ANAVEX LIFE SCIENCES CORP. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- ANAVEX LIFE SCIENCES CORP. reported Stockholders Equity of $94.87 million for fiscal year 2025.
- ANAVEX LIFE SCIENCES CORP. showed a decrease of -21.1% in Stockholders Equity compared to the prior fiscal year.
- ANAVEX LIFE SCIENCES CORP. reported R&D Expense of $37.59 million for fiscal year 2025.
- ANAVEX LIFE SCIENCES CORP. showed a decrease of -10.1% in R&D Expense compared to the prior fiscal year.
- ANAVEX LIFE SCIENCES CORP. reported Operating Income of -$51.41 million for fiscal year 2025.
- ANAVEX LIFE SCIENCES CORP. showed an increase of +2.8% in Operating Income compared to the prior fiscal year.
- ANAVEX LIFE SCIENCES CORP. reported Shares Outstanding of 86.67 million shares for fiscal year 2025.
- ANAVEX LIFE SCIENCES CORP. showed an increase of +2.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: